WCM
RLAY icon

Westend Capital Management’s Relay Therapeutics RLAY Stock Holding History

Westend Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-77
Closed -$639 – 307
2024
Q1 		$639 Buy
+77
New +$751 ﹤0.01% 301

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Westend Capital Management's RLAY Position: Q2 2024 in Review

Westend Capital Management sold out of Relay Therapeutics (RLAY) in Q2 2024, closing a stake of 77 shares — an estimated $639 sold.

Westend Capital Management first reported a position in RLAY in Q1 2024 and held it in 1 quarter. The position peaked at $639 in Q1 2024. 178 funds tracked by Wall St. Rank hold RLAY as of Q2 2024.

  • Westend Capital Management reported no remaining Relay Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Westend Capital Management sold 77 Relay Therapeutics shares in Q2 2024, an estimated $639.
  • Westend Capital Management first reported a position in Relay Therapeutics in Q1 2024 and held it in 1 quarter.
  • Westend Capital Management's Relay Therapeutics position peaked at $639 in Q1 2024.
  • 178 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2024.

Based on Westend Capital Management's 13F filing for Q2 2024, filed 8 Jul 2024.